Background: Methotrexate (MTX) is widely used as a cytotoxic chemotherapeutic agent for malignancies as well as in the treatment of various inflammatory diseases. MTX treatment has been associated with renal toxicity. The current study was conducted to assess the potential protective role of N-acetylcysteine and/or melatonin in attenuation of methotrexate-induced renal damage in MTX intoxicated male albino rats.
INTRODUCTION
Methotrexate's primary route of elimination is renal. Patients with a potential for impaired renal function HDMTX-associated severe acute renal failure (ARF) is an infrequent but serious complication because MTX is predominantly excreted in the urine. Data from a number of studies performed in the 1970s showed that a sustained elevation of serum MTX concentrations at 24 h (≥5 μmol/L), 48 h (≥1 μmo/L) and 72 h (≥0.1 μmo/L) after the start of the MTX infusion is considered to be toxic. The usual serum MTX level 48 h after HDMTX is <0.1 μmol/L (Widemann BC, Adamson PC 2006) .
Many drugs have been tested with the aim of preventing radiocontrastinduced nephropathy, and in 2000, NAC was discovered for this purpose (Tepel and Zidek 2004) .
NAC has, however, rapidly become widely used for kidney protection (Pannu et al., 2004) .Several metaanalyses have also been published; some concluded that NAC, when added to conventional hydration, decreases the risk of radiocontrast nephropathy in patients with chronic renal failure (Duong et al., 2005 Sixty, apparently healthy, adult male albino rats (150+10 gm body weight) were obtained from Animal house of Faculty of Medicine-Cairo University. They were housed in hygienic metal cages and kept in a clean well ventilated room. They were fed on standard laboratory diet and allowed free access to water. Rats were left for two weeks before commencement of the study to be acclimatized to lab conditions. All rats were weighed weekly in order to adjust the dose of drugs according to body weight. All doses were given once daily for 12 weeks. 
RESULTS
No difference was observed between the negative and positive control groups concerning the Creatinine levels.
At the end of the fourth week, the creatinine level of the Methotrexatetreated group (group 4) increased about 4.77 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 5), the creatinine level decreased significantly about 22.1% as compared to that of the Methotrexate-treated group, but still 3.7 times higher than that of the negative control group (P< 0.000). With the use of the Melatonin (group 6), the creatinine level was insignificantly decreased as compared to that of the Methotrexate-treated group, but still 27.4 %higher than that of the MTX-N-acetylcysteine treated group. It was about 4.7 times higher than that of the negative control group (P< 0.000).At the end of the eighth week, the creatinine level of the Methotrexate-treated group (group 4) increased about 5.2 times than that of With the use of the N-acetylcysteine (group 5), the creatinine level decreased significantly about 32.6% as compared to that of the Methotrexatetreated group, but still it was about 3.5 times higher than that of the negative control group (P< 0.000). With the use of the Melatonin (group 6), the creatinine level was insignificantly decreased as compared to that of the Methotrexate-treated group (group 4), but still it was about 30.9% higher than that of the MTX-N-acetylcysteine treated group (group 5). It was about 4.6 times higher than that of the negative control group (P< 0.000).At the end of twelve weeks, the creatinine level of the Methotrexate-treated group (group 4) increased about 6 times than that of the negative control group (P< 0.000). With the use of the Nacetylcysteine(group 5), the creatinine level decreased significantly about 42.6% as compared to that of the Methotrexate-treated group(group 4), but still 3.47 times higher than that of the negative control group (P< 0.000).
With the use of the Melatonin (group 6), the creatinine level was insignificantly decreased as compared to that of the Methotrexate-treated group(group 4), but still 65% higher than that of the MTX-N-acetylcysteine treated group (group 5). It was about 4.8 times higher than that of the negative control group (P< 0.000) ( Table 1) .
The renal cortex of the control group showed numerous renal corpuscles and convoluted tubules of the renal cortex. Each renal corpuscle appeared as a dense, rounded structure formed of glomerulus surrounded by a narrow capsular (urinary) space, followed by a single row of flat squamous cells of the parietal layer of Bowman's capsule (Figure 1) .
The renal cortex of the Methotrexate-treated group (group 4) showed cytoplasmic vacuolation and pyknosis of the nuclei of theproximal convoluted tubules (PCT). In addition the tubular epithelium exhibited exfoliation with intraluminal cast formation. Multiple glomeruli were atrophic with widening of the urinary spaces. The peritubular capillaries were congested ( Figure 2&3) . Improvement of the histological appearance was observed in the renal cortex of the NAC-treated group (group 5). The glomeruli were nearly normal with a slight widening of the urinary spaces. Some pathological findings were found in the renal tubular epithelium in the form of pyknosis of the nuclei, exfoliation, cytoplasmic vacuolation with tubular cast formation (Figure 4) .
More deterioration of the renal cortex was observed in the melatonintreated group (group 6). Severe congestion of the glomeruli and of the peritubular capillaries was observed, which led finally to massive vascular extravasation. The tubular epithelium showed pyknosis and apoptosis of the nuclei of the PCT. In addition, cytoplasmic vacuolation, exfoliation with the tubular cast formation were constant findings in the tubules of this group This biochemical dysfunction in the methotrexate-treated group (group 4) was in harmony with the morphological abnormalities of the examined renal sections that revealed maximal affection of the renal cortex of rats that received MTX only (group 4) in the form of a condensation of chromatin (pyknosis) Intraluminal cast formation of the renal tubules was also noticed in the methotrexate-treated group (group 4) following the intraluminal exfoliation of the lining epithelial cells. Goligorsky and his co-workers declared that the necrotic epithelial cells provided a matrix for intraluminal cast formation (Goligorsky et al., 1993) .Furthermore, the renal tubules of the methotrexatetreated group (group 4) showed the presence of cytoplasmic vacuolization of the lining epithelial cells which might be due to the disturbance of the sodium pump, as a sequence of impaired oxidative phosphorylation, which results in hydropicdegeneration (Therien and Blostein, 2000).
The current study revealed that the most sensitive part of the kidney to the toxic effects of MTX was the epithelium of the PCT. This could be explained by the wide distribution of the enzymes needed for the uptake of MTX such as the apical gammaglutamyltranspeptidase, glucose-6 phosphatase, alkaline phosphatase, ATPase and succinic dehydrogenase in the cells of the PCT (Diamond and Zalups, 1998).
N-acetylcysteine, derived from the simple amino acid cysteine, provides significant protection against a broad array of modern toxins. These include acrolein (found in cigarette smoke and In the present work, benificial effect on creatinine levels was recorded on supplementation of N-acetylcysteine concomitantly with methotrexate in group 5; it reduced creatinine levels significantly when compared to the non-supplemented group 4 that was treated with MTX (P< 0.000) in all intervals.
Tepel et al., 2000 demonstrated that administration of NAC reduced contrast media nephrotoxicity. This demonstration was based on a milder elevation of serum creatinine following administration of contrast medium when associated with NAC. The morphological changes and histopathologic findings of the kidney sections were significantly milder when NAC was co-administered with MTX in groups 5 as compared to the effects of MTX when used alone in group 4. Agrawal et al., 2008 concluded that it might be useful to use NAC to minimize MTX-induced nephrotoxicity as evidenced by the improvement of the glomerular and the peritubular capillaries congestion (Agrawal et al.,  2008) .
On the other hand, the use of the melatonin in combination with methotrexate in group 6 produced minimal non-significant reduction of the creatinine level relative to group 4 at the 4 th , 8 th and 12 th weeks (P> 0.05). This observed chemical effect in group 6 was supported by the deterioration of the renal cortical structure as observed in the melatonin and MTX group (group 6). These results were inconsistent with those of Kilic et al., (2013) who reported that both serum creatinine and urea nitrogen increased significantly following cisplatin administration alone and these values decreased significantly with melatonin co-treatment of cisplatin-treated rats. This discrepancy observed in the protective effect of melatonin on the kidney could be attributed to the difference in the experimental protocol as Kilic et al., (2013) administered melatonin two days before the single intraperitoneal injection of cisplatin.
In conclusion, in the present work, benificial effect on creatinine levels was recorded on supplementation of Nacetylcysteine concomitantly with methotrexate in group 5; it reduced creatinine levels significantly when compared to the non-supplemented group 4 that was treated with MTX (P< 0.000) in all intervals.
In the view of the present study, we recommend to conduct the same study on human beings in order to investigate the feasibility and suitability of the results of the present study on human beings. 
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